Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Homology Medicines, Inc. (FIXX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
07/27/2023 8-K Cost Associated with Exit or Disposal Activities, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/04/2023 8-K Investor presentation
Docs: "Corporate Slide Presentation of Homology Medicines, Inc."
09/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement, between Homology Medicines, Inc. and Arthur O. Tzianabos, Ph.D",
"Amendment to Employment Agreement, between Homology Medicines, Inc. and W. Bradford Smith"
06/16/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
04/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Employment Agreement, between Homology Medicines, Inc. and Albert Seymour, Ph.D"
03/16/2022 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...
Docs: "Unaudited Pro Forma Condensed Consolidated Balance Sheet as of September 30, 2021 and Unaudited Pro Forma Condensed Consolidated Statements of Operations for the year ended December 31, 2020 and the nine months ended September 30, 2021"
02/18/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU"
02/02/2022 8-K Quarterly results
06/21/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
04/09/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
02/08/2021 8-K Quarterly results
01/06/2021 8-K Investor presentation
Docs: "Corporate Slide Presentation of Homology Medicines, Inc.",
"Corporate Slide Presentation of Homology Medicines, Inc."
12/18/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws of Homology Medicines, Inc"
11/09/2020 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Secur...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"STOCK PURCHASE AGREEMENT",
"Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc."
07/21/2020 8-K Quarterly results
06/11/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/19/2019 8-K Quarterly results
07/15/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Homology Medicines Appoints Alise Reicin, M.D., to the Board of Directors"
06/27/2019 8-K Quarterly results
06/10/2019 8-K Submission of Matters to a Vote of Security Holders
04/11/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : April 9, 2019 HOMOLOGY MEDICINES, INC. Delaware 001-38433 47-3468154 One Patriots Park Bedford, MA 01730 301-7277 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act )...",
"Underwriting Agreement, by and among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Cowen and Company, LLC, as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP"
04/08/2019 8-K Results of Operations and Financial Condition, Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : April 4, 2019 HOMOLOGY MEDICINES, INC. Delaware 001-38433 47-3468154 One Patriots Park Bedford, MA 01730 301-7277 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act )..."
04/01/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Sales Agreement, between Homology Medicines, Inc. and Cowen and Company, LLC (incorporated by reference to Exhibit 1.2 to the Company's Registration Statement on Form S-3 (Reg. No. 333-230664) filed on April 1, 2019)"
04/03/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : April 2, 2018 HOMOLOGY MEDICINES, INC. Delaware 001-38433 47-3468154 45 Wiggins Avenue Bedford, MA 01730 301-7277 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act )...",
"Restated Certificate of Incorporation of Homology Medicines, Inc",
"Amended and Restated Bylaws of Homology Medicines, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy